Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy
/in International Publications, Newcastle Disease Virus, NSCLC /von 2015-11-15 / Am J Cancer Res 2015;5(12):3612-23Vaccine immunotherapy in lung cancer: Clinical experience and future directions
/in International Publications, NSCLC, SCLC /von 2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-9Immunotherapy for lung cancer: for whom the bell tolls?
/in Dendritic Cells, International Publications, NSCLC /von 2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-22Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
/in Hyperthermia, International Publications, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-26Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-9Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-09-25 / Oncol Lett 2014 Dec;8(6):2569-2576Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-07-30 / BMC Cancer 2014 Jul;14:551
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de